Abstract
ST-segment elevation myocardial infarction (STEMI) is still a major public health problem in the modern world. Therapeutic options have changed much over the last 20 years, with a shift in favor of mechanical reperfusion over pharmacologic reperfusion. Thrombolytic therapy still has much to offer in the management of STEMI, however, because many patients do not have timely access to a facility with the required expertise for establishing mechanical reperfusion. This review highlights the history of thrombolytic therapy, adjunctive therapies, the relationship with mechanical reperfusion, and potential roles for thrombolysis in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 617-637 |
| Number of pages | 21 |
| Journal | Medical Clinics of North America |
| Volume | 91 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 2007 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Thrombolysis in Acute Myocardial Infarction: Current Status'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver